As big pharmas including Takeda and Novo Nordisk flee the cell therapy space and smaller biotechs shutter their operations, ...

In patients naïve to HER2-targeted therapy, the objective response rate was 71% with a median duration of response of 9.2 months.

Bayer’s sevabertinib picks up a second-line indication for HER2-mutated disease, joining Boehringer’s zongertinib on the US ...

The FDA announced accelerated approval of sevabertinib (Hyrnuo) for HER2-positive non-small cell lung cancer (NSCLC).

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the first patient has been dosed in the Phase 1/2 study evaluating CRN09682 in patients with metastatic or locally advanced somatostatin ...

The US Patent and Trademark Office has issued a new patent (US Patent No. 12,472,263) on additional and novel formulations of ...

A 23-month-old with a history of Hirschsprung disease was referred for evaluation of a persistent, severe diaper rash ...

The therapeutic landscape for hepatocellular carcinoma (HCC) has been revolutionized by the advent of molecular targeted therapies and immune ...

The FDA has granted an accelerated approval to sevabertinib (Hyrnuo) for the treatment of adult patients with previously ...

The accelerated FDA approval of Bayer's Hyrnuo covers treatment of advanced cases of non-small cell lung cancer with HER2 ...

Dr. Carrie Jose, in her latest Health and Wellness column, explains if your metabolism could be the real culprit to your ...

Voranigo (vorasidenib), a drug for certain brain tumors, was safe and well toleratedin patients with grade 3 or 4 IDH-mutant ...